Savara (NASDAQ:SVRA) Shares Up 7.2% – Here’s Why

Savara Inc. (NASDAQ:SVRA) shares were up 7.2% on Wednesday. The stock traded as high as $5.05 and last traded at $4.9850. 360,182 shares traded hands during trading, a decline of 78% from the average session volume of 1,671,651 shares. The stock had previously closed at $4.65.

Analyst Upgrades and Downgrades

A number of research firms have commented on SVRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Sunday. JPMorgan Chase & Co. assumed coverage on Savara in a research note on Wednesday. They issued an “overweight” rating and a $12.00 price target for the company. Royal Bank Of Canada set a $10.00 price target on shares of Savara in a report on Wednesday. Finally, Citigroup restated a “market outperform” rating on shares of Savara in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.25.

Savara Stock Performance

The business has a 50-day moving average of $5.35 and a 200 day moving average of $5.42. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The company has a market cap of $1.03 billion, a PE ratio of -8.68 and a beta of 0.20.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities research analysts anticipate that Savara Inc. will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in shares of Savara by 96.5% during the first quarter. Renaissance Technologies LLC now owns 652,672 shares of the company’s stock valued at $3,564,000 after buying an additional 320,572 shares during the last quarter. Walleye Capital LLC acquired a new position in Savara in the 2nd quarter worth approximately $1,532,000. BlackRock Inc. acquired a new position in shares of Savara in the 2nd quarter valued at about $76,966,000. Deutsche Bank AG purchased a new stake in Savara during the second quarter worth $5,328,000. Finally, Nantahala Capital Management LLC acquired a new stake in Savara in the second quarter valued at approximately $42,977,150. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.